Wanbury has received Certificate of Suitability (CEP) from European Directorate for the Quality of Medicines (EDQM) for its Dextromethorphan active pharmaceutical ingredient (API), antitussive (cough) medicine. The global formulation market for Dextromethorphan is valued at $2,500 million for FY24, having grown by 7% over the past year. With the CEP certification, Wanbury is well positioned to initiate the commercial sales of this product in European markets.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
